Fri, 21 May 2010
Paper Discussed: Ng JQ, Morlet N, Pearman JW, et al. Management and outcomes of postoperative endophthalmitis since the endophthalmitis vitrectomy study: the Endophthalmitis Population Study of Western Australia (EPSWA)'s fifth report. Ophthalmology, July 2005, 112(7) p1199-206 Guest: Jonathon Q. Ng, MBBS, BA Research Associate School of Population Health The University of Western Australia Crawley, Australia
|
Fri, 21 May 2010
Paper Discussed: Santos M, Gomes J, Hofling-Lima A, et al. Survival Analysis of Conjunctival Limbal Grafts and Amniotic Membrane Transplantation in Eyes With Total Limbal Stem Cell Deficiency American Journal of Ophthalmology, August 2005, 140(2) p223.e1-223.e10 Guest: Myrna SerapiÃo dos Santos, M.D. Specialist in External Ocular Diseases and Cornea Vision Institute of the Federal University of SÃo Paulo-Brazil Researcher at the Advanced Center of Ocular Surface Vision Institute-Federal Post-Doctoral Fellow at the Cornea Sector University of Rome Campus Bio-Medico Rome, Italy
|
Fri, 21 May 2010
Subject: part 2 of CNV and Anti-VEGF Therapy Paper Discussed: Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology, June 2005, 112(6) p1035-47 Guest: Philip J. Rosenfeld, M.D., Ph.D. Associate Professor of Ophthalmology Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, Florida
|
Fri, 21 May 2010
Paper Discussed: Chang TC, Congdon NG, Wojciechowski R, et al. Determinants and heritability of intraocular pressure and cup-to-disc ratio in a defined older population. Ophthalmology, July 2005, 112(7) p1186-91 Guest: Nathan Congdon, MD, MPH Associate Professor of Ophthalmology and International Health Johns Hopkins University Schools of Medicine and Public Health Baltimore, Maryland
|
Fri, 21 May 2010
Subject: part 1: CNV and Anti-VEGF Therapy Paper Discussed: Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology, June 2005, 112(6) p1035-47 Guest: Philip J. Rosenfeld, M.D., Ph.D. Associate Professor of Ophthalmology Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, Florida
|
Sat, 15 May 2010
Guest: Chris Teng, MD Clinical Assistant Professor New York Medical College New York Eye and Ear Infirmary New York, NY |
Wed, 5 May 2010
Guest: Nisha Acharya, MD, MS |
